KLHL17: A Potential Drug Target and Biomarker (G339451)

Target Name: KLHL17

NCBI ID: G339451

KLHL17: A Potential Drug Target and Biomarker

Kelch-like 17 (KLHL17) is a protein that is expressed in various tissues, including the brain, heart, and pancreas. It is a member of the Kelch family of proteins, which are involved in a variety of cellular processes, including cell signaling, cytoskeletal organization, and stress response. The KLHL17 protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The KLHL17 protein is composed of 215 amino acid residues and has a calculated molecular mass of 29.9 kDa. It is expressed in a variety of tissues, including the brain, heart, and pancreas, and is highly expressed in the liver. KLHL17 is involved in the regulation of cellular processes that are critical for maintaining normal cellular function and has been implicated in a number of diseases.

One of the most promising aspects of KLHL17 is its potential as a drug target. KLHL17 has been shown to play a role in a variety of cellular processes that are involved in cancer progression, including cell signaling, angiogenesis, and immune surveillance. In addition, KLHL17 has been shown to be involved in the regulation of cellular stress responses, which are critical for maintaining cellular homeostasis in the face of environmental stressors, such as stress, UV radiation, and chemicals.

KLHL17 has also been shown to be involved in the regulation of cellular memory and learning. In addition, it is involved in the regulation of cellular processes that are critical for maintaining normal cellular function, including cell division, apoptosis, and inflammation.

As a potential drug target, KLHL17 has the potential to be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, KLHL17 has been shown to play a role in the regulation of cancer cell growth and has been shown to be involved in the development of various types of cancer, including breast, ovarian, and prostate cancer.

In addition, KLHL17 has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In these conditions, KLHL17 has been shown to play a role in the regulation of neurotransmitter synthesis and release, as well as the regulation of cellular stress responses.

In addition to its potential as a drug target, KLHL17 also has the potential as a biomarker for a variety of diseases. For example, KLHL17 has been shown to be involved in the regulation of cellular stress responses, which are critical for maintaining cellular homeostasis in the face of environmental stressors. This makes KLHL17 an attractive candidate as a biomarker for stress-related diseases, including anxiety, depression, and PTSD.

In addition, KLHL17 has also been shown to be involved in the regulation of cellular signaling pathways that are critical for maintaining normal cellular function. This makes KLHL17 an attractive candidate as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Overall, KLHL17 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of KLHL17 in cellular processes and to develop effective treatments for the treatment of these diseases.

Protein Name: Kelch Like Family Member 17

Functions: Substrate-recognition component of some cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes. The BCR(KLHL17) complex mediates the ubiquitination and subsequent degradation of GLUR6. May play a role in the actin-based neuronal function (By similarity)

More Common Targets